August 7, 2025 — Leads & Copy — aTyr Pharma, Inc. (Nasdaq: ATYR) announced its second quarter 2025 results and provided a corporate update. The company’s Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis is on track to report topline data in mid-September.
According to Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer of aTyr, the completion of the last patient visit in the EFZO-FIT™ study is a major inflection point for aTyr, its clinical program for efzofitimod in ILD, and the broader sarcoidosis community.
The Phase 3 EFZO-FIT™ study evaluated the efficacy and safety of efzofitimod in patients with pulmonary sarcoidosis. It enrolled 268 patients across 85 centers in nine countries. Interim data from the ongoing Phase 2 EFZO-CONNECT™ study to evaluate efzofitimod in patients with systemic sclerosis-related ILD (SSc-ILD) showed stable or improved modified Rodnan Skin Score (mRSS) for all patients.
aTyr advanced ATYR0101 to investigational new drug (IND) candidate stage for pulmonary fibrosis. The Company anticipates filing an IND application in the second half of 2026. The company was also added to the Russell 2000® Index and broad market Russell 3000® Index.
As of June 30, 2025, aTyr’s cash, cash equivalents, restricted cash and available-for-sale investments were $83.2 million. Subsequent to the end of the second quarter 2025, the Company raised approximately $30.7 million in gross proceeds from its at-the-market (ATM) offering with Jefferies LLC.
R&D expenses were $15.4 million for the second quarter 2025, while G&A expenses were $4.9 million.
Efzofitimod is a biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD). aTyr is investigating efzofitimod in Phase 3 and Phase 2 studies for pulmonary sarcoidosis and systemic sclerosis-related ILD, respectively.
aTyr is a clinical stage biotechnology company translating tRNA synthetase biology into new therapies for fibrosis and inflammation.
Ashlee Dunston, Sr. Director, Investor Relations and Public Affairs, adunston@atyrpharma.com
Source: aTyr Pharma, Inc.
